Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1005
http://purl.obolibrary.org/obo/NCIT_C1005
|
|---|---|
| Preferred Name | Arsenic Trioxide |
| Definitions |
A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04) |
|---|---|
| prefLabel | Arsenic Trioxide
|
| label | Arsenic Trioxide
|
| CHEBI_ID | CHEBI:30621
|
| PDQ_Closed_Trial_Search_ID | 43067
|
| code | C1005
|
| Has_Target | |
| prefixIRI | NCIT:C1005
|
| in_subset |
See more
See less
|
| Display_Name | Arsenic Trioxide
|
| Preferred_Name | Arsenic Trioxide
|
| FDA_UNII_Code | S7V92P67HO
|
| Is_PCDC_AML_Permissible_Value_For_Variable | |
| Contributing_Source |
CTRP
FDA
PCDC
|
| Chemical_Formula | As2O3
|
| Maps_To | Arsenic Trioxide
|
| CAS_Registry | 1327-53-3
|
| NSC Number | 706363
|
| NCI_Drug_Dictionary_ID | 43067
|
| Legacy Concept Name | Arsenic_Trioxide
|
| type | |
| ALT_DEFINITION | A drug used to treat acute promyelocytic leukemia (APL) that has not gotten better or that has come back after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43067
|
| Accepted_Therapeutic_Use_For | Myelodysplastic syndrome; multiple myeloma; chronic myeloid leukemia; acute myelocytic leukemia
|
| Semantic_Type |
Pharmacologic Substance
Inorganic Chemical
|
| UMLS_CUI | C0052416
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |